See more : The Interpublic Group of Companies, Inc. (IPG) Income Statement Analysis – Financial Results
Complete financial analysis of Avanos Medical, Inc. (AVNS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avanos Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Yushin Precision Equipment Co., Ltd. (6482.T) Income Statement Analysis – Financial Results
- MIE Holdings Corporation (1555.HK) Income Statement Analysis – Financial Results
- Keisei Electric Railway Co., Ltd. (9009.T) Income Statement Analysis – Financial Results
- Firebird Metals Limited (FRB.AX) Income Statement Analysis – Financial Results
- L’Air Liquide S.A. (AIL.DE) Income Statement Analysis – Financial Results
Avanos Medical, Inc. (AVNS)
About Avanos Medical, Inc.
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 673.30M | 820.00M | 744.60M | 714.80M | 697.60M | 652.30M | 611.60M | 1.59B | 1.57B | 1.67B | 1.68B | 1.68B | 1.66B |
| Cost of Revenue | 293.60M | 370.00M | 380.30M | 341.50M | 295.40M | 261.40M | 274.70M | 1.03B | 1.04B | 1.12B | 1.07B | 1.08B | 1.07B |
| Gross Profit | 379.70M | 450.00M | 364.30M | 373.30M | 402.20M | 390.90M | 336.90M | 557.90M | 531.60M | 548.60M | 612.20M | 602.50M | 590.80M |
| Gross Profit Ratio | 56.39% | 54.88% | 48.93% | 52.22% | 57.65% | 59.93% | 55.09% | 35.04% | 33.77% | 32.81% | 36.49% | 35.78% | 35.59% |
| Research & Development | 27.20M | 30.60M | 32.30M | 34.90M | 37.70M | 41.80M | 38.20M | 41.10M | 32.30M | 33.60M | 37.90M | 33.00M | 31.20M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 340.40M | 321.70M | 411.10M | 398.50M | 424.50M | 351.40M | 343.00M | 351.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 318.10M | 341.90M | 300.30M | 332.60M | 399.10M | 340.40M | 321.70M | 411.10M | 398.50M | 424.50M | 351.40M | 343.00M | 351.70M |
| Other Expenses | 0.00 | 3.50M | 22.80M | 51.90M | 21.10M | 8.20M | 20.10M | 18.30M | 4.50M | -3.80M | -2.40M | -1.50M | -2.80M |
| Operating Expenses | 375.50M | 376.00M | 355.40M | 419.40M | 457.90M | 390.40M | 380.00M | 470.50M | 435.30M | 454.30M | 386.90M | 374.50M | 380.10M |
| Cost & Expenses | 669.10M | 746.00M | 735.70M | 760.90M | 753.30M | 651.80M | 654.70M | 1.50B | 1.48B | 1.58B | 1.45B | 1.46B | 1.45B |
| Interest Income | 2.90M | 1.20M | 200.00K | 1.20M | 6.70M | 7.80M | 2.50M | 600.00K | 300.00K | 2.90M | 2.60M | 2.60M | 4.10M |
| Interest Expense | 15.00M | 10.00M | 3.30M | 15.60M | 15.00M | 26.40M | 31.60M | 32.70M | 33.10M | 6.00M | 100.00K | 800.00K | 200.00K |
| Depreciation & Amortization | 46.10M | 41.10M | 38.30M | 42.90M | 36.90M | 33.50M | 40.00M | 41.00M | 65.40M | 85.40M | 69.20M | 57.60M | 51.10M |
| EBITDA | 50.60M | 77.80M | 8.90M | -2.00M | -12.10M | 65.70M | -600.00K | -65.50M | -76.50M | 179.70M | 297.10M | 288.20M | 265.90M |
| EBITDA Ratio | 7.52% | 14.99% | 6.37% | -0.28% | -1.73% | 6.41% | 3.09% | 9.62% | 10.29% | 10.92% | 17.71% | 17.11% | 16.02% |
| Operating Income | 4.20M | 74.00M | 8.90M | -46.10M | -55.70M | 500.00K | -43.10M | 87.40M | -377.70M | 94.30M | 225.30M | 228.00M | 210.70M |
| Operating Income Ratio | 0.62% | 9.02% | 1.20% | -6.45% | -7.98% | 0.08% | -7.05% | 5.49% | -23.99% | 5.64% | 13.43% | 13.54% | 12.69% |
| Total Other Income/Expenses | -12.10M | -8.80M | 44.80M | -14.40M | -8.30M | -18.60M | -29.10M | -32.10M | -274.80M | -3.10M | 2.50M | 1.80M | 3.90M |
| Income Before Tax | -7.90M | 65.20M | 5.80M | -60.50M | -64.00M | -18.10M | -72.20M | 55.30M | -410.50M | 91.20M | 227.80M | 229.80M | 214.60M |
| Income Before Tax Ratio | -1.17% | 7.95% | 0.78% | -8.46% | -9.17% | -2.77% | -11.81% | 3.47% | -26.07% | 5.45% | 13.58% | 13.65% | 12.93% |
| Income Tax Expense | 2.00M | 14.70M | 600.00K | -33.30M | -18.10M | -9.60M | -40.10M | 15.50M | 15.80M | 64.10M | 73.20M | 77.20M | 72.20M |
| Net Income | -61.80M | 50.50M | 6.30M | -27.20M | -45.90M | 57.50M | 79.30M | 39.80M | -426.30M | 27.10M | 154.60M | 152.60M | 142.40M |
| Net Income Ratio | -9.18% | 6.16% | 0.85% | -3.81% | -6.58% | 8.81% | 12.97% | 2.50% | -27.08% | 1.62% | 9.22% | 9.06% | 8.58% |
| EPS | -1.33 | 1.08 | 0.13 | -0.57 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 | 3.06 |
| EPS Diluted | -1.33 | 1.07 | 0.13 | -0.57 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 | 3.06 |
| Weighted Avg Shares Out | 46.60M | 46.90M | 48.10M | 47.80M | 47.60M | 47.20M | 46.52M | 46.60M | 46.59M | 46.54M | 46.51M | 46.51M | 46.51M |
| Weighted Avg Shares Out (Dil) | 46.60M | 47.30M | 48.60M | 47.80M | 47.60M | 47.20M | 46.80M | 47.00M | 46.59M | 46.54M | 46.51M | 46.51M | 46.51M |
New Strong Sell Stocks for January 9th
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Avanos Medical, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Avanos Medical, Inc. and Encourages Investors with Losses to Contact the Firm
Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales
Avanos Medical, Inc. Reports Preliminary Fourth Quarter and Full-Year 2023 Financial Results; Revises Preliminary 2024 Revenue Outlook
Avanos Medical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Avanos Medical (AVNS) Up 0.1% Since Last Earnings Report: Can It Continue?
Avanos Medical, Inc. to Present at the Stifel 2023 Healthcare Conference
Avanos Medical Inc. (AVNS) Q3 2023 Earnings Call Transcript
Avanos (AVNS) Q3 Earnings Top Estimates, Margins Contract
Source: https://incomestatements.info
Category: Stock Reports